Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Claire on +441494 818 025 or claire@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
Director
claire@zenopa.com
+441494 818 025

Testimonials
I would like to thank Zenopa for assisting me in finding my new role in Neuro Medical Device Sales. My experience was positive with Zenopa from the date I registered to the date I received the offer.
Craig, 2012

Boehringer Ingelheim reports positive data for lung cancer therapy

17 May 2012 11:14 in Pharmaceutical Company Product News


Boehringer Ingelheim has reported encouraging new results from a phase III trial of afatinib, its therapy for EGFR mutation-positive and advanced metastatic non-small cell lung cancer.

The company has concluded a pivotal study called LUX-Lung 3, the largest and most robust trial conducted among this patient group to date, in order to assess the efficacy of afatinib compared to the current standard first-line treatment.

It was found that Boehringer Ingelheim's therapy offers a number of potential advantages, which will be further investigated in the subsequent LUX-Lung 7 and 8 trials.

Full data from LUX-Lung 3 will be showcased next month at the American Society of Clinical Oncology's annual meeting.

Dr Mehdi Shahidi, global clinical development team leader for oncology at Boehringer Ingelheim, said: "The results will be particularly important for EGFR mutation-positive patients and underline our commitment to advance personalised care for lung cancer patients."

Last month, the company reported its financial results for the 2011 business year, during which it experienced annual sales growth of 6.2 percent.ADNFCR-8000103-ID-801365190-ADNFCR

Other news stories from 17/05/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd